Precigen stock jumps after Q1 2026 beat (PGEN:NASDAQ)
Precigen (PGEN) shares rose by approximately 12% after the biotech company reported stronger-than-expected Q1 2026 financials. The positive performance was attributed to the successful launch of its new cancer therapy, Papzimeos, contributing an additional $23.3 million in revenue compared to the previous year.
This Biotech Has Soared Nearly 200% In A Year — Now Analysts See More Upside Ahead
Precigen Inc. (PGEN) shares soared over 26% in pre-market trading after its laryngeal cancer treatment, Papzimeos, exceeded analyst expectations, driving a strong Q1 revenue beat. Citizens and H.C. Wainwright raised their price targets on PGEN, citing positive sales performance and strong potential for its HPV cancer therapy candidate, PRGN-2009, which is currently in Phase 2 clinical trials. The company anticipates achieving cash flow break-even by the end of 2026, supported by Papzimeos sales.
H.C. Wainwright raises Precigen stock price target on strong Papzimeos sales
H.C. Wainwright increased its price target for Precigen Inc. (NASDAQ:PGEN) to $11.00 from $10.00, maintaining a Buy rating, following impressive first-quarter 2026 sales of Papzimeos, which significantly exceeded expectations. First-quarter sales reached $21.6 million, a substantial increase from the prior quarter, and the company is expected to achieve profitability this year with projected EPS of $0.06 for fiscal 2026. This positive outlook is further supported by the recent granting of a permanent J-code for Papzimeos and strong anticipated sales growth, leading H.C. Wainwright to raise its fiscal 2026 sales forecast for the product to $130 million.
Earnings call transcript: Precigen Inc. Q1 2026 sees revenue surge
Precigen Inc. reported better-than-expected Q1 2026 financial results, with revenue surging to $23.3 million, driven primarily by the commercial success of PAPZIMEOS. The company posted an EPS of -$0.02, beating forecasts, and saw its stock rise in after-hours trading. Precigen remains optimistic about continued revenue growth and aims to achieve cash flow breakeven by the end of 2026 without needing additional capital market funding.
PAPZIMEOS launch powers Precigen (PGEN) Q1 2026 revenue jump and smaller loss
Precigen (PGEN) reported significantly improved financial results for Q1 2026, primarily driven by the strong U.S. launch of its drug PAPZIMEOS for recurrent respiratory papillomatosis, generating $21.6 million in sales. Total revenues surged to $23.3 million from $1.3 million year-over-year, and the net loss narrowed considerably to $7.9 million from $54.2 million. The company expects current cash, investments, and PAPZIMEOS collections to fund operations to cash flow break-even by the end of 2026.
Earnings Flash (PGEN) Precigen, Inc. Reports Q1 Revenue $23.3M, vs. FactSet Est of $20.8M
Precigen, Inc. (PGEN) reported its Q1 revenue at $23.3 million, exceeding FactSet's estimated $20.8 million. The biopharmaceutical company specializes in gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. This announcement also notes their Q1 earnings call and other financial results for the quarter.
Earnings Flash (PGEN) Precigen, Inc. Reports Q1 Revenue $23.3M, Vs. FactSet Est of $20.8M
Precigen, Inc. (PGEN) announced its fiscal first-quarter earnings, reporting revenue of $23.3 million. This figure exceeded the FactSet estimate of $20.8 million, indicating a stronger-than-expected financial performance for the quarter.
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen Inc. is set to announce its full-year 2024 financial results and provide business updates on March 19th. This information was disseminated via Quantisnow, a real-time market data and news platform that alerts subscribers to such events. Quantisnow provides real-time alerts on various market activities including SEC filings, FDA approvals, analyst ratings, insider trades, and press releases for retail investors.
Precigen Inc expected to post a loss of 3 cents a share - Earnings Preview
Precigen Inc is projected to report a loss of 3 cents per share, according to this earnings preview. The article details the market's expectation for the company's upcoming financial results, which are provided by Refinitiv.
Did Strong Early PAPZIMEOS Revenue Guidance Just Shift Precigen's (PGEN) Investment Narrative?
Precigen announced that its Q1 2026 PAPZIMEOS revenue is expected to surpass US$18,000,000, indicating early commercial traction for its rare disease platform. This strong guidance, coupled with an expert consensus endorsing PAPZIMEOS as the first-line standard of care for RRP, suggests a potential positive shift in the company's investment narrative by validating demand despite ongoing reimbursement challenges. Investors are focusing on whether this revenue growth can outpace commercial and manufacturing costs and overcome reimbursement hurdles.
Precigen earnings on deck: Can Papzimeos deliver on lofty sales target?
Precigen Inc. is preparing to report its first-quarter earnings, with significant attention on whether its new gene therapy, Papzimeos, can meet ambitious sales targets. Analysts anticipate a substantial improvement in revenue and a reduced loss per share, reflecting strong expectations for the recently launched treatment for recurrent respiratory papillomatosis. The company's ability to achieve projected sales acceleration and progress towards cash-flow break-even will be key points of interest for investors.
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. (Nasdaq: PGEN) will release its first-quarter 2026 financial results and provide business updates on Wednesday, May 13, 2026. The company will host a conference call at 4:30 PM ET on the same day to discuss the results. Precigen specializes in developing innovative precision medicines for difficult-to-treat diseases.
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. (Nasdaq: PGEN) announced it will release its first quarter 2026 financial results and provide business updates on Wednesday, May 13, 2026. The biopharmaceutical company will host a conference call on the same day at 4:30 PM ET to discuss the results. Interested participants can find event details on Precigen's investor relations website.
Precigen earnings on deck: Can Papzimeos deliver on lofty sales target?
Precigen is set to report its first-quarter earnings, with focus on whether its recently launched gene therapy, Papzimeos, can meet ambitious sales guidance of over $18 million for the quarter. Analysts are bullish on the stock, with a mean price target of $9.50, implying a significant upside. Investors will be watching Papzimeos's sales acceleration, patient adoption, and the company's path to cash-flow break-even.
Precigen to Announce First Quarter 2026 Financial Results on May 13
Precigen, Inc. (NASDAQ: PGEN) is set to announce its first-quarter 2026 financial results and provide business updates on May 13, 2026. The company will host a conference call and webcast on the same day at 4:30 PM Eastern Time to discuss these results. Interested parties can access the live webcast via the Investors section of Precigen's website or register in advance for dial-in details.
May 13 at 4:30 ET: Precigen pairs Q1 results with business update
Precigen (Nasdaq: PGEN) will release its first quarter 2026 financial results and provide business updates on May 13, 2026, with a conference call scheduled for 4:30 PM ET on the same day. The company expects Q1 2026 revenue to exceed $18 million, building on strong uptake of PAPZIMEOS and a cash balance of $100.4 million as of December 31, 2025. Investors are advised to call in 10-15 minutes early and can find access details on Precigen's investor relations website.
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. (Nasdaq: PGEN) will release its first-quarter 2026 financial results and provide business updates on Wednesday, May 13, 2026. The biopharmaceutical company will host a conference call on the same day at 4:30 PM ET to discuss the results. Interested parties can access the call via phone or through the company's investor relations website.
Assessing Precigen (PGEN) Valuation As Papzimeous Launch Marks Shift To Commercial Rare Disease Platform
Precigen (PGEN) is transitioning into a commercial rare disease platform following the launch of Papzimeous, with its stock currently trading at $4.33 against an analyst target of $9.50. While a narrative suggests fundamental undervaluation at $8.50, driven by anticipated revenue growth and market expansion, the company's high P/B ratio of 73.3x indicates a rich valuation that may already price in significant future expectations. Investors are advised to examine key risks and warnings to form their own view.
[ARS] PRECIGEN, INC. SEC Filing
This article announces an ARS SEC filing by Precigen, Inc. (PGEN) on April 30, 2026. The filing has a low impact and neutral sentiment, and the full document is available in PDF format. The page also provides a company overview, recent news, and latest SEC filings for PGEN.
[DEF 14A] PRECIGEN, INC. Definitive Proxy Statement
Precigen, Inc. (PGEN) is holding its 2026 Annual Meeting on June 18, 2026, where shareholders will vote on key proposals including the election of nine directors, the ratification of Deloitte & Touche LLP as its independent auditor, an advisory vote on 2025 executive compensation, and an amendment to increase the shares available under the 2023 Omnibus Incentive Plan by 7 million. The company's 2025 performance highlights include FDA approval and initial launch of Papzimeos, and the proxy statement details corporate governance, director and executive pay, and beneficial ownership.
Top Growth Companies With Insider Stakes In April 2026
This article identifies top growth companies in the United States with significant insider ownership, highlighting that such ownership often indicates management's confidence in future prospects. It features a list of ten companies, including Uxin, Upstart Holdings, and Precigen, and provides detailed profiles for Prenetics Global, Precigen, and Diana Shipping, discussing their growth forecasts, insider activities, and financial outlooks. The piece underscores the importance of aligning shareholder and management interests in a market showing flat performance recently but strong annual growth over the past year.
Top Growth Companies With Insider Stakes In April 2026
This article identifies top growth companies in the United States with significant insider ownership, highlighting that high insider stakes often signal management confidence. It features a list of ten such companies and provides brief analyses of Prenetics Global (PRE), Precigen (PGEN), and Diana Shipping (DSX), detailing their growth forecasts, insider ownership, and financial situations. The report also notes the overall flat performance of the US market in the last week, contrasting with a 30% rise over the past year.
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Hold" by Analysts
Analysts have given Precigen, Inc. (NASDAQ:PGEN) a consensus "Hold" recommendation, with an average 1-year target price of $9.50 based on reports from seven brokerages. While the company's latest quarterly EPS of ($0.01) beat estimates, revenue missed at $4.57 million against an expected $8.29 million, and it remains unprofitable with a negative net margin of 2,588.21%. Additionally, a director recently sold a significant portion of shares, reducing his ownership by over 94%.
Precigen (PGEN) CFO receives 120,000 RSUs and options on 399,000 shares
Precigen, Inc.'s CFO, Harry Thomasian Jr., has received compensation-related equity grants, including 120,000 Restricted Stock Units (RSUs) and options to purchase 399,000 shares of common stock at an exercise price of $4.11 per share. Both the options and RSUs will begin vesting on May 23, 2027, with the options vesting monthly over three years and the RSUs vesting in six-month installments over the same period. This filing reflects awards granted rather than open-market transactions.
Precigen (PGEN) COO Rutul Shah receives new RSU and stock option grants
Precigen's Chief Operating Officer, Rutul Shah, has been granted 118,000 restricted stock units (RSUs) and options for 395,000 shares of common stock. These equity awards are part of his compensation, with both the RSUs and options set to begin vesting on May 23, 2027, over a period of three years, aligning his long-term interests with the company's performance. The stock options have an exercise price of $4.11 per share.
Precigen (PGEN) awards CCO 115,000 RSUs and 385,000 options
Precigen, Inc. has awarded its Chief Commercial Officer, Phil Tennant, 115,000 restricted stock units (RSUs) and 385,000 stock options. The options have an exercise price of $4.11 per share and expire on April 20, 2036. Both the RSUs and options begin vesting 25% on May 23, 2027, with the remainder vesting monthly for options and semi-annually for RSUs over three years.
Precigen (PGEN) CEO receives large RSU and stock option grants
Precigen (PGEN) CEO Helen Sabzevari was granted 410,000 Restricted Stock Units and options on 1,366,000 shares of common stock with an exercise price of $4.11 per share. These equity awards are part of her compensation, with vesting schedules designed to align her interests with shareholder value over several years. No shares were sold in these transactions, as indicated in the Form 4 SEC filing.
Precigen (PGEN) awards RSUs and stock options to Chief Legal Officer
Precigen (PGEN) has granted its Chief Legal Officer, Donald P. Lehr, new equity awards consisting of 107,000 Restricted Stock Units (RSUs) and 358,000 stock options. These awards, valued at a $4.11 exercise price for the options, are compensation-related and will vest over several years, with the first 25% vesting on May 23, 2027. This information was detailed in a recent SEC Form 4 filing.
Is Precigen’s (PGEN) New PAPZIMEOS J-Code Reframing Its Respiratory Growth Narrative?
Precigen (PGEN) recently received a permanent J-code (J3404) for its lead respiratory treatment, PAPZIMEOS, which simplifies reimbursement and expands patient access. The company expects first-quarter sales of PAPZIMEOS to exceed US$18 million, reinforcing confidence in the drug's demand and commercialization efforts. This development, coupled with a US$125 million credit facility, provides Precigen with more flexibility despite the challenge of managing high fixed costs.
Is Precigen’s (PGEN) New PAPZIMEOS J-Code Reframing Its Respiratory Growth Narrative?
Precigen Inc. (PGEN) expects Q1 PAPZIMEOS sales to exceed US$18 million after receiving a permanent J-code (J3404) from the Centers for Medicare & Medicaid Services, enhancing reimbursement and patient access. This development, along with a US$125 million credit facility, is seen as bolstering the company's commercialization efforts and its path toward cash flow breakeven. However, investors are cautioned about the risk of revenue lagging fixed costs, despite an optimistic revenue forecast of $299.5 million by 2028.
Is Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?
Precigen Inc. (PGEN) is identified as a top healthcare penny stock by hedge funds, with its lead respiratory treatment, PAPZIMEOS, expected to see a significant sales increase in Q1, exceeding $18 million. The company is experiencing strong momentum with increased patient enrollment and has received a permanent J-code for PAPZIMEOS, streamlining the claims process. Precigen, a commercial-stage biopharmaceutical company, is also pursuing European market authorization for its treatment.
A Look At Precigen (PGEN) Valuation As PAPZIMEOS Commercial Launch And J Code Spark Investor Interest
Precigen (PGEN) is gaining investor interest following FDA approval and commercial launch of PAPZIMEOS, alongside a new CMS J-code. Despite a significant share price increase and a bullish analyst target of US$9.50, suggesting undervaluation, a high P/B ratio of 70.6x raises questions about justified future expectations. Investors are advised to consider both the growth narrative and potential risks.
Precigen, Inc. (PGEN) poised for growth on respiratory papillomatosis treatment prospects
This article discusses Precigen, Inc.'s potential for growth, particularly highlighting its promising advancements in treating recurrent respiratory papillomatosis. The company's therapies are expected to drive future revenue and market expansion. Investors are keenly watching the development of these treatments.
CapEx per share of Precigen Inc – SWB:I5X
This page from TradingView provides financial information specifically focusing on the Capital Expenditure (CapEx) per share for Precigen Inc, traded on the Stuttgart Stock Exchange under the ticker SWB:I5X. It indicates that the market is currently closed and briefly mentions data provided by ICE Data Services, FactSet, and SEC filings by Quartr. The primary content for the user would be a table or graph showing the CapEx per share over different periods.
PGEN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Precigen Inc (PGEN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Collaboration and licensing agreements are the primary revenue driver, contributing 62.2% of its total sales. PGEN exhibits a strong gross margin of 65.04% but reports negative operating and net margins, alongside a significantly negative Return on Equity, indicating operational challenges.
Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025
Precigen Inc. reported $3.4 million in net product sales for its immunotherapy PAPZIMEOS in Q4 2025, with shipments starting in November. The company, valued at $1.48 billion, saw a 147% revenue growth and expects Q1 2026 revenue to exceed $18 million. PAPZIMEOS received full FDA approval in August 2025 for treating recurrent respiratory papillomatosis (RRP) and has been recommended as a first-line treatment, contributing to a 215% increase in share price over the past year.
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Precigen Inc. (NASDAQ:PGEN) announced strong initial adoption of its new immunotherapy, PAPZIMEOS, for recurrent respiratory papillomatosis (RRP), leading to an expected Q1 2026 revenue exceeding $18 million. The FDA-approved treatment addresses the root cause of RRP, a rare respiratory disease, and the company is now planning for pediatric trials and European approval. This success marks a transition for Precigen from an R&D company to a product revenue-generating biotech.
Precigen Reports Strong Demand for New Rare Disease Drug
Precigen Inc., a biopharmaceutical company, has reported strong demand for its new drug treating a rare respiratory disease, expecting over $18 million in first-quarter revenue. The company plans to expand the drug's use to pediatric patients and seek European regulatory approval. This successful launch and planned expansion highlight the drug's potential to significantly improve the quality of life for affected patients.
Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025 By Investing.com
Precigen Inc. reported $3.4 million in net product sales for its immunotherapy PAPZIMEOS in Q4 2025, with shipments beginning in November. The company, valued at $1.48 billion, saw a 147% revenue growth over the past year and expects Q1 2026 revenue to exceed $18 million. PAPZIMEOS, an FDA-approved treatment for recurrent respiratory papillomatosis (RRP), has received positive analyst ratings and has driven Precigen's shares up 215% over the last year.
Rare disease drug aimed at reducing surgeries lifts Precigen Q1 view above $18M
Precigen (NASDAQ: PGEN) is seeing a "robust uptake" of its new drug PAPZIMEOS, an FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), expecting Q1 2026 revenue to exceed $18 million. The company reported $3.4 million in net product sales in Q4 2025, with patient hub enrollment surpassing 300. Precigen is also pursuing pediatric trials for RRP and European approval for PAPZIMEOS, positioning the drug as a new standard of care that reduces the need for frequent surgeries in RRP patients.
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Precigen Inc. (NASDAQ:PGEN) announced "robust uptake" of its new immunotherapy, PAPZIMEOS, for recurrent respiratory papillomatosis (RRP), leading to an expected revenue exceeding $18 million in the first quarter of 2026. The Centers for Medicare & Medicaid Services (CMS) assigned a J-code to the therapy, streamlining reimbursement, and an expert consensus paper published in The Laryngoscope recommends PAPZIMEOS as the new standard-of-care for adult RRP. The company is now planning to expand the drug's use to pediatric patients and seek European approval.
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Precigen Inc. reports "robust uptake" of its new immunotherapy PAPZIMEOS for recurrent respiratory papillomatosis (RRP) since its August 2025 launch. The company expects first-quarter 2026 revenue to exceed $18 million for the drug. Plans are underway to expand its use to pediatric patients and secure European approval, with a J-code now assigned by CMS to streamline reimbursement.
Precigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment Prospects
Precigen, Inc. (PGEN) is expected to grow due to its lead drug, PAPZIMEOS, a fully FDA-approved immunotherapy for recurrent respiratory papillomatosis. Analysts at Citizens reiterated a Market Outperform rating and increased the price target to $9, citing strong commercial metrics and the drug's positioning as the first and only approved therapy for the condition. The company anticipates over $18 million in PAPZIMEOS sales in Q1 following its approval last year.
Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?
Precigen (PGEN) experienced a 7.4% stock increase after reporting a significant rise in 2025 revenue to US$9.68 million, alongside a widened net loss of US$250.64 million. This article examines how these results, particularly the substantial net loss, impact the investment outlook for Precigen and its primary therapy, PAPZIMEOS. While revenue growth is encouraging, the increased losses highlight the importance of successful commercialization and raise concerns about short-term dilution and financing risks.
PGEN Should I Buy
Precigen Inc (PGEN) is recommended as a good buy for beginner long-term investors due to strong Q4 financial performance, positive analyst ratings, and promising commercial traction for PAPZIMEOS. Despite hedge fund selling, technical indicators and options data suggest a neutral to slightly positive sentiment, making it a reasonable entry point. Analysts have raised price targets to $9-$10, citing strong sales and reinforcing the company's growth potential.
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 4,772,781 Shares of Stock
Precigen Director Randal Kirk sold 4,772,781 shares of PGEN stock on March 30th at an average price of $3.30, totaling over $15.75 million and reducing his position by 94.05%. Following the sale, Kirk now owns 302,213 shares. The company recently beat EPS estimates but missed revenue, and analysts have a "Hold" consensus rating with a $9.50 average price target for the biotechnology firm.
PGEN SEC Filings - Precigen Inc 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Precigen Inc.'s (PGEN) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 reports. It highlights key corporate events such as a senior secured term loan facility of up to $125 million, an exclusive commercial supply agreement for PAPZIMEOS with Catalent, and an S-3 shelf registration for resale of common and preferred shares by insiders. The filings also detail the company's financial condition, regulatory progress for PRGN-2012, and insider equity transactions, with AI-powered summaries and sentiment analysis provided by Stock Titan.
Randal J. Kirk (PGEN) entities sell 4.8M shares, still hold over one-third stake
Entities controlled by Randal J. Kirk sold 4,772,781 shares of Precigen (PGEN) Common Stock for approximately $15.58 million on March 30, 2026. Despite these sales, Kirk and his affiliated entities, including R.J. Kirk Declaration of Trust and Third Security, LLC, collectively retain beneficial ownership of 133,956,416 shares, representing 35.9% of the company's outstanding Common Stock. The filing clarifies the adjusted ownership percentages and the calculation basis, including exercisable options and warrants.
Assessing Precigen (PGEN) Valuation After Wider 2025 Loss And Earnings Release
Precigen (PGEN) recently reported its full year 2025 results, showing revenue of US$9.68 million and a net loss of US$250.64 million, leading to a wider loss than expected. Despite a volatile stock performance, with recent gains but a 90-day decline, the company is seen as significantly undervalued by analysts, with a fair value estimate of $8.50 compared to its current trading price of US$3.87. This optimism is largely driven by the potential rapid uptake of PAPZIMEOS, though its sustained traction and reimbursement status pose key risks.
PGEN PE Ratio & Valuation, Is PGEN Overvalued
This article analyzes the valuation of Precigen Inc (PGEN), determining that it is currently in the "Fair zone" based on its forward PS ratio. It details various valuation metrics like P/B ratio and FCF yield, comparing them to historical averages and industry benchmarks. The analysis suggests that PGEN's premium P/S ratio is sustainable given its robust revenue growth.
